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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not “Is spinal 
cord stimulation an effective therapy to treat severe lower extremity painful diabetic peripheral 
neuropathy that has lasted over one year and has not responded to medical therapy?” 
 
Study Design: A review of two RCTs and one case series published in English in 2014.  
 
Data Sources: Two RCTs and one case series found via PubMed that evaluated the benefit of 
spinal cord stimulation (SCS) versus best medical treatment (BMT) to treat severe painful 
diabetic peripheral neuropathy (PDPN).  
 
Outcome(s) Measured: The amount of pain a patient experiences, measured using either a 
visual analogue scale with 0 representing no pain and 100 representing the worst pain 
imaginable, or measured with a numeric rating scale. 
 
Results: All three studies found a significant decrease in pain levels in patients receiving SCS 
treatment for severe PDPN compared to patients receiving BMT. In the Abd-Elsayed et al. case 
series, a patient with PDPN reported a 60% overall decrease in pain 1 month post SCS 
implantation. In the De Vos et al. RCT, the average visual analogue scale (VAS) pain score in 
patients receiving SCS was reduced from 73/100 to 31/100 (P < 0.001), while the VAS pain 
score in the control group remained 67/100. 60% of patients in the SCS group experienced at 
least 50% pain reduction, while only 5% of patients in the control group experienced 50% pain 
reduction. In the Slangen et al. RCT, treatment success was observed in 59% of patients 
receiving SCS, while success was observed only in 7% of patients receiving BMT (P < 0.01).  
 
Conclusions: Based on these three studies, pain is significantly decreased in patients 
experiencing severe PDPN when treated with spinal cord stimulation compared to best medical 
therapy. The spinal cord stimulator implantation is a surgical procedure that has risks that 
patients should be made aware of prior to treatment. However, in patients where benefits 
outweigh the risks, SCS should be considered a treatment option for severe PDPN.  
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INTRODUCTION 
 Diabetes Mellitus (DM) is a chronic disease that occurs when the body does not make 
enough insulin or develops a resistance to insulin, leading to elevated blood glucose levels 
(hyperglycemia).1 Type 1 diabetes manifests earlier in life, while type 2 manifests later, usually 
from a lifetime of poor diet and lack of exercise. Uncontrolled diabetes has a variety of 
complications, including stroke, heart disease, heart attack, and neuropathy. Nerve damage, 
leading to painful diabetic peripheral neuropathy, may result in patients that have had diabetes 
for an extended period of time or have had difficulty controlling their blood glucose levels.1 The 
exact cause of PDPN is unknown, however researchers believe that diabetic neuropathies are due 
to a number of factors, including: high blood glucose, abnormal blood fat levels, low insulin, 
neurovascular factors, nerve inflammation, mechanical injury, genetics, and lifestyle factors. 
These patients may experience numbness, tingling, burning, weakness, loss of reflexes, loss of 
coordination, and pain as the nerve damage progresses.1 This can happen in any area of the body: 
the arms, legs, digestive tract, and sex organs. The most common type of diabetic neuropathy 
affects the periphery, which causes symptoms in arms or legs.1 
 It is estimated that a total of 23.1 million people in the US have a diagnosis of diabetes 
and approximately 7.2 million people have diabetes but remain undiagnosed.2 These 7.2 million 
people are likely to have uncontrolled blood glucose levels and are therefore at an increased risk 
of developing complications of diabetes, like PDPN. It is estimated that 60-70% of patients with 
diabetes will develop some type of neuropathy.1  
 The CDC estimates that a total of 14.2 million emergency department visits in 2014 had 
diabetes listed as a diagnosis, including 207,000 visits for hyperglycemia and 245,000 visits for 
hypoglycemia.2 In addition, the estimated total direct and indirect cost for diabetes is $245 
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billion in the US alone. Average medical expenses are approximately 2.3 times higher in patients 
with diabetes than without.2 The more complications that exist, the more the cost increases.  
 The first line treatment of diabetic complications is to gain and maintain control of blood 
glucose levels through blood glucose monitoring, diet, exercise, and medications that help to 
decrease blood glucose like Metformin and Insulin.1 It is also very important that diabetic 
patients see their primary care physician and have their feet checked regularly. Most diabetic 
patients have regular appointments every three to six months for blood work, including a 
Hemoglobin A1c, which measures the average blood glucose level over three months. For 
PDPN, pain relief can be gained through a variety of medications, including: antidepressants, 
anticonvulsants, and opioid or opioid like drugs. Duloxetine and Pregabalin are approved by the 
FDA specifically for treating PDPN.1 These medications often come with side effects and are not 
always approved for use in older individuals. Over the counter medications such as ibuprofen 
and acetaminophen generally do not work well for nerve pain. Lastly, topical treatments, like 
capsaicin cream and lidocaine, are available and are most commonly applied to the feet. These 
medications are relatively safe but do not necessarily provide relief.1 
 The above listed treatment options have been found to be the most effective medical 
options thus far in treating pain associated with PDPN, and therefore are deemed the “best 
medical therapy” (BMT). However, they are often accompanied by side effects and are not 
effective enough in relieving pain. Several studies have shown that spinal cord stimulation has 
been more effective than BMT in treating pain associated with PDPN. The mechanism of action 
of spinal cord stimulation has not been fully uncovered, but it is thought to be multifactorial.3 
The spinal cord level at which the SCS is placed is dependent on the location of symptoms, but is 
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generally in the thoracic region. This paper evaluates two randomized controlled trials (RCTs) 
and one case series that show the efficacy of SCS compared to BMT in treating severe PDPN.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “Is spinal cord 
stimulation an effective therapy to treat severe lower extremity diabetic peripheral neuropathy 
pain that has lasted over one year and has not responded to medical therapy? 
METHODS 
 Two randomized controlled trials and one case series were used in this review. The 
population includes men and women over the age of 18 with type 1 or type 2 diabetes mellitus 
experiencing moderate to severe lower extremity painful diabetic peripheral neuropathy for at 
least one year that has not been successfully treated by BMT. The intervention used in the two 
RCTs was SCS along with BMT. The control group received BMT alone. In the case series, the 
intervention was spinal cord stimulation. All three studies found a significant decrease in pain 
levels in patients receiving SCS treatment for severe PDPN compared to patients receiving BMT 
only.  
 The key words used in searching for the articles addressed in this review included the 
following: diabetic neuropathy, neuropathic pain, and spinal cord stimulation. All three articles 
were published in English in peer-reviewed journals. The articles were selected based on 
relevance to the clinical question and if they addressed outcomes that were patient oriented 
evidence that matters (POEMs). The inclusion criteria included RCTs and other studies 
published after 2006. Studies that were excluded were those published before 2006, those that 
involved patients less than 18 years of age, and those discussing upper extremity or mild PDPN. 
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Statistics reported included the following: p-value, ABI, RRI, NNT, and NNH. Specific 
demographics and characteristics of each of the studies are detailed in Table 1 below.  
 
Table 1- Demographics and Characteristics of included studies 
 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W
/D 
Interventions 
Abd-
Elsayed, 
et al. 
(2014)4 
Case 
Series 
3 79, 
60, 
39 
Patients with 
resistant painful 
peripheral 
neuropathy 
There were no patients 
excluded in this study.  
0 Implantation of 
a spinal cord 
stimulator 
De Vos, 
et al. 
(2014)5 
RCT 60 >18 
years 
old 
Patients that were 
evaluated and 
diagnosed with 
diabetic 
neuropathy by a 
neurologist, had 
refractory diabetic 
neuropathic pain 
in the lower 
extremities for >1 
year, and had an 
average pain score 
of >50 on a visual 
analogue scale 
(VAS).  
Patients with pain due 
to atherosclerotic 
lesions, patients with 
infection, neuropathic 
pain in upper 
extremities, coagulation 
disorders or taking 
anticoagulant 
medication, patients 
with psychiatric 
disorders, and patients 
addicted to drugs or 
alcohol.  
6 Implantation of 
a spinal cord 
stimulator over 
the physiologic 
midline with the 
tip of the 
electrode lead 
between 
vertebral levels 
T9 and T12. 
Medication 
adjustments and 
PT were allowed 
at any time at 
the discretion of 
the physician.  
Slangen, 
et al.  
(2014)6 
RCT 36 18-
80 
years 
old 
Patients with 
moderate to severe 
PDPN present in 
the lower limbs, 
experiencing 
insufficient pain 
relief and/or 
unacceptable side 
effects with drug 
treatment, with 
pain present <12 
months, and a 
mean pain 
intensity daytime 
or nighttime of >5 
on a NRS.  
Patients with 
neuropathic pain in 
upper limbs, 
neuropathy of origin 
other than DM, recent 
neuro-modulation 
therapy, drug or alcohol 
abuse, blood clotting 
disorders, immune 
deficiency, PV disease, 
active foot ulcers, life 
expectancy <1 year, 
pacemakers, local 
infection, psychiatric 
disorders, pregnancy, 
cardiac or pulmonary 
failure, unstable 
glucose control, or use 
of anticoagulants. 
2 Implantation of 
spinal cord 
stimulator with 
the lead 
positioned over 
the thoracic 
level and 
settings tailored 
to each patient.  
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OUTCOMES MEASURED 
 All three studies measured pain, reported by the patients. In the Abd-Elsayed, et al. case 
series, pain was measured using a visual analogue scale (VAS), from 0-10, with 0 representing 
no pain and 10 representing maximum pain. Pain was measured at baseline and 1-month post 
SCS implantation.4 In the De Vos, et al. RCT, pain was measured using a VAS, from 0-100, with 
0 representing no pain and 100 representing the worst pain imaginable. Pain was measured at 
baseline, 1 month, 3 months, and 6 months. Treatment success was defined as a greater than 50% 
reduction in pain on the VAS.5 In the Slangen, et al. RCT, pain was measured using a numeric 
rating scale (NRS), from 0-10, with 0 representing no pain and 10 representing maximum pain. 
Pain was measured at baseline, 3 months, and 6 months. Treatment success was defined as a 
greater than 50% relief of daytime or nighttime pain intensity on the NRS for at least 4 days.6  
RESULTS 
 Two RCTs and one case series evaluated the efficacy of spinal cord stimulation as 
management for painful diabetic peripheral neuropathy. The Abd-Elsayed, et al. case series 
describes three patients with peripheral neuropathy: 1) a 79-year-old male with bilateral lower 
extremity painful diabetic peripheral neuropathy for 11 years, 2) a 60-year-old male with HIV- 
induced neuropathy for 15 years, and 3) a 39-year-old female with neuropathy secondary to 
chemotherapy for 3 years.4 These patients had failed best medical therapy and therefore SCS was 
presented as an option to manage their pain. All three patients experienced a reduction in pain 
with the one-week trial period of the spinal cord stimulator. Patient 1 and patient 3 elected to 
receive the permanent SCS implantation and continued to experience pain reduction. Patient 2 
did experience pain relief with the SCS trial, however his health declined and he elected to 
postpone the implantation.4 The patient most relevant to this study, patient 1, reported improved 
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VAS scores with the trial and after implantation reported an overall 60% pain reduction. In 
addition, he reported improved activities of daily living such as walking and grocery shopping, 
and breakthrough oral pain medications were successfully weaned down.4 The results are 
displayed below in Table 2.  
Table 2- Abd-Elsayed, et al.4 VAS scores and pain reduction 
Patient Baseline VAS 
pain score 
VAS score after 
1 week of trial 
SCS 
VAS score after 
implantation 
Percent 
reduction in 
pain from 
baseline 
1 9/10 3/10 2/10 60% 
2 9/10 Not reported Not reported 95% 
3 8/10 Not reported Not reported  95% 
 
 In De Vos, et al., a RCT, a total of 60 patients with an average VAS pain score of at least 
50/100 were selected and randomized in a 2:1 fashion to either the SCS with BMT group, or the 
BMT only group.5 For all patients in both groups, adjustments in BMT, including medications 
and physical therapy, were allowed at any time throughout the duration of the study. All patients 
were followed up at 1 month, 3 months, and 6 months to assess pain on a VAS. Two patients 
failed to follow up for their 1 month visit and four patients failed to follow up at the 3 month 
visit. Data analysis was performed regardless. Treatment success was defined as a greater than 
50% reduction in pain.5 After 6 months, the SCS group had a 60% success rate, while the control 
group had only a 5% success rate (p < 0.001), showing a significant difference in treatment effect 
between groups (Table 3).5 RBI was calculated to be 11, ABI was calculated to be 0.55, and 
NNT was calculated to be 2. This is significant because it means that two patients would need to 
be treated in order for one patient to see a benefit compared to the control. Detailed calculations 
can be seen in Table 4 below. This study was not without adverse events. A total of six patients 
withdrew from the study: four from the SCS group and two from the control group. Therefore, 
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the study contained 36 patients in the SCS group and 18 patients in the BMT group. From the 
SCS group, one patient could not get the implant, two patients did not get any relief in the trial, 
and one patient left this study for another. In the control group, two patients withdrew due to 
unrelated illnesses.5 In the SCS group; there were two cases of infections, one femur fracture, 
one cardiac arrest, and four patients that needed repositioning of the SCS device. In the control 
group, there were two infections, one carotid artery stenosis, one myocardial infarction, one 
atrial fibrillation episode, and one coronary bypass surgery. All adverse events were treated and 
resolved during the study period.5  
Table 3- De Vos, et al.5 treatment outcomes  
 VAS baseline 
(out of 100) 
VAS 6 months 
(out of 100) 
Treatment 
success 
SCS group 73 (SD=16) 31 (SD= 28)* 60%  
Control group 67 (SD=18) 67 (SD=18)** 5% 
*P<0.001, significant treatment effect within group 
**P<0.001, significant treatment effect between groups 
SD = standard deviation 
 
Table 4- Calculations for treatment success from De Vos, et al. 
 Relative benefit increase (RBI) 
Absolute benefit 
increase (ABI) 
Number needed to 
treat (NNT) 
CER EER EER- CER CER EER - CER 1/ABI 
0.05 0.60 11 0.55 2 
 
 In Slangen, et al., a RCT, 36 patients with severe PDPN not responding to best medical 
therapy were randomly assigned in a 3:2 fashion to either SCS with BMT or BMT only.6 
Twenty-two patients were assigned to the SCS group, while 14 were assigned to the BMT only 
group. Patients were followed at 3 months and 6 months. Treatment success was defined as 
greater than 50% reduction in daytime or nighttime pain for at least four days. At 6 months, 
treatment success in the SCS grouped was reported in 13 out of 22 patients (59%) and 1 out of 
14 (7%) in the control group (p < 0.009).5 In addition, 41% of patients in the SCS group reported 
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greater than 50% daytime pain relief compared to 0% in the control group (P < 0.001), while 
36% in the SCS group reported greater than 50% of nighttime pain relief compared to 7% in the 
control group (P < 0.01).6 These results can be seen in Table 5. RBI was calculated to be 7.43, 
ABI was calculated to be 0.52, and NNT was calculated to be 2 for treatment success. This is 
significant because it means that two patients would need to be treated for one patient to see a 
benefit compared to the control. Detailed calculations are shown in Table 6. Two patients 
withdrew from the study: one patient in the SCS group contracted an infection six weeks after 
the implantation and had the SCS removed and another patient suffered from a dural puncture 
during SCS implantation, subsequently dying from a subdural hematoma.6 The NNH is 11, 
which is significant because it means that if 11 patients are exposed to SCS implantation, an 
average of one more patient will have an adverse event that they would not have had otherwise. 
Detailed calculations can be seen in Table 7.  
Table 5- Slangen, et al.6 Treatment outcomes 
 SCS Group Control Group P-Value 
Treatment success 13/22 (59%) 1/14 (7%) P < 0.009* 
> 50% reduction on 
NRS for daytime pain 
9/22 (41%) 0/14 (0%) P < 0.001** 
> 50% reduction on 
NRS for nighttime pain 
8/22 (36%) 1/14 (7%) P < 0.01*** 
*P < 0.009, significant treatment effect between groups 
**P<0.001, significant treatment effect between groups 
***P<0.01, significant treatment effect between groups 
 
Table 6- Calculations for treatment success from Slangen, et al. 
 Relative benefit increase (RBI) 
Absolute benefit 
increase (ABI) 
Number needed to 
treat (NNT) 
CER EER EER- CER CER EER - CER 1/ABI 
0.07 0.59 7.43 0.52 2 
 
 
 
 
 
Brecht, Efficacy of SCS in treating PDPN  9	
 
Table 7- Calculations for harm from Slangen, et al. 
 Relative risk increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
CER EER EER- CER CER EER - CER 1/ARI 
0 0.09  0.09 11 
 
DISCUSSION 
 Diabetes is a very common condition and if uncontrolled can come with an array of 
complications, including PDPN.2 While medical treatment is an option, it is not always the 
safest, not always cost effective, and more importantly for patients it does not always relieve 
pain. This review evaluates an alternative treatment for painful diabetic peripheral neuropathy: 
spinal cord stimulation. Each study discussed contains limitations. First, this study was restricted 
to severe peripheral neuropathic pain that was only located in the lower extremities. Spinal cord 
stimulation as a treatment for mild neuropathic pain or pain in the upper extremities was not 
addressed, and the results cannot be generalized.  In addition, these studies evaluated spinal cord 
stimulation for patients that have suffered from pain for a long time, in some cases many years, 
and these patients have already failed best medical therapy. It is unknown if SCS would be an 
effective treatment in patients with severe pain that have not tried BMT for as long or do not use 
BMT in combination with the stimulator. Lastly, in the two RCTs, there have not been published 
studies following these patients after the final six month follow up. It is unknown if the spinal 
cord stimulators continued to be effective or if they caused any long-term complications.  
 Spinal cord stimulators have been studied for a variety of indications, including: failed 
back surgery syndrome, complex regional pain syndrome, intractable angina, neuropathic pain 
secondary to HIV, and neuropathic pain secondary to chemotherapy.3 Caution is recommended 
in patients with coagulopathy, pacemakers, and certain psychological conditions. An active 
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systemic or local infection is a contraindication for SCS trial and implantation (aside from HIV), 
but the implantation can be performed once the infection is cleared.3  
 Studies involving spinal cord stimulators are limited in terms of their concealment and 
blinding. First, patients receiving BMT only knew that they were not receiving the spinal cord 
stimulator because it is unethical to undergo a surgical procedure and implant a device that 
would not be used. Likewise, patients receiving the spinal cord stimulator knew that they were 
receiving the experimental treatment, because it is unethical to perform a surgery without the 
patients’ knowledge. In the De Vos, et al. RCT, patients in the control group were offered to 
receive SCS therapy at the conclusion of the study if they desired it.5  
CONCLUSION 
 All three studies demonstrated that spinal cord stimulation is an effective alternative 
treatment for severe painful diabetic peripheral neuropathy in patients over the age of 18 that 
have failed best medical therapy. The complications of diabetes can be very debilitating and 
more concrete evidence of an effective treatment is necessary. Further studies should address 
patients with diabetes that are experiencing other types of neuropathic pain, including upper 
extremity peripheral neuropathy and more proximal neuropathy that affects the thighs, hips, and 
buttocks.1 Patients may also experience autonomic neuropathy affecting the digestive tract, 
sexual response, the heart, and the lungs.1 Treatments should be evaluated for all types of 
neuropathy. Along with this, the safety of a spinal cord stimulator being placed higher on the 
spine will have to be evaluated. This will allow the stimulator to relieve symptoms along other 
areas of the body. Despite the range of use that spinal cord stimulation is being evaluated for and 
the success presented in this review, it is still a fairly new subject that will require expanded 
research before it can be used as common practice in treating neuropathic pain. 
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